A Phase 1 interventional study of KCP-330 in Sarcoma, sponsored by Karyopharm Therapeutics Inc. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-08.
Sponsored by Karyopharm Therapeutics Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 244 under way, 4 of them phase 3. Sarcoma · United States.
Among the 958 studies in Sarcoma with a site in United States, this one is the 281st largest by enrollment of the 800 interventional ones that give a count, is one of 22 that started in 2013, is one of 281 in phase 1, and was the 460th registered.
1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
Browse Sarcoma studies →153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 65–100
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Iovance Biotherapeutics, Inc. · Sites in United States
Ages 16–70
St. Jude Children's Research Hospital · Sites in United States
City of Hope Medical Center · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
958 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 393 · Phase 2 426 · Phase 3 42 · Phase 4 4
First in 1983; this study’s year is marked. 22 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is above the median of 41 across 1,254 interventional studies indexed under Sarcoma.
Median enrollment 35 across the 800 interventional studies, 101 across the 100 observational. Of the 650 that completed or were terminated, 245 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
231 of 958 have an industry lead sponsor. The 10 most frequent:
Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Karyopharm Therapeutics Inc has 2 studies filed under Sarcoma — fewer than ten, so there is no comparison to draw.
78 of the studies in Sarcoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01223248Phase 3Memorial Sloan Kettering Cancer CenterRandomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | 2027-10 |
| NCT02307630Memorial Sloan Kettering Cancer CenterPET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study | 2026-11 |
| NCT05099666Massachusetts General HospitalLurbinectedin + Doxorubicin In Leiomyosarcoma | 2026-12 |
| NCT03114527Fox Chase Cancer CenterPhase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | 2026-12 |
| NCT00582647Memorial Sloan Kettering Cancer CenterCollection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract | 2026-12 |
Add all 78 to your calendar (.ics) → With an account.
Among the 958 studies in Sarcoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to find out more information such as: to determine the effects of high and low fat foods on the pharmacokinetics (PK) of oral KPT-330 tablets and to compare PK of capsules and tablets in Arms 1 and 2; to evaluate tumor response in sarcoma participants in Arm 3; to compare the PK of 60 milligrams (mg) of the new, 2nd generation tablet formulation and 60 mg of the selinexor suspension formula to the current, 1st generation tablets.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 30 milligrams per meter square (mg/m\^2) orally twice weekly in treatment sequence ABCD (Treatment A: fasted, tablet formulation on Day 1 of Week 1; Treatment B: high-fat meal, tablet formulation on Day 1 of Week 2; Treatment C: low-fat meal, tablet formulation on Day 1 of Week 3; Treatment D: low-fat meal, capsule formulation on Day 1 of Week 4 in Cycle 1 (Weeks 1 to 4).
Drug: KCP-330
Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received selinexor 30 mg/m\^2 orally twice weekly in treatment sequence BADC (Treatment B: high-fat meal, tablet formulation on Day 1 of Week 1; Treatment A: fasted, tablet formulation on Day 1 of Week 2; Treatment D: low fat meal, capsule formulation on Day 1 of Week 3; Treatment C: low-fat meal, tablet formulation on Day 1 of Week 4 in Cycle 1 (Weeks 1 to 4).All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.
Drug: KCP-330
Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 50 mg/m\^2 first generation tablets twice weekly on Days 1 and 3 of each week within 30 minutes of solid food consumption.
Drug: KCP-330
Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 60 mg/m\^2 orally in treatment sequence ABC (Treatment A: current \[1st generation\] tablets on Day 1 of Week 1; Treatment B: new \[2nd generation\] tablets on Day 1 of Week 2; Treatment C: suspension dose of current \[1st generation\] tablets on Day 1 of Week 3 in Cycle 1 (Weeks 1 to 3). All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.
Drug: KCP-330
Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 60 mg/m\^2 orally in treatment sequence CAB (Treatment C: suspension dose of current \[1st generation\] tablets on Day 1 of Week 1; Treatment A: current \[1st generation\] tablets on Day 1 of Week 2; Treatment B: new \[2nd generation\] tablets on Day 1 of Week 3 in Cycle 1 (Weeks 1 to 3). All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.
Drug: KCP-330
Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 60 mg/m\^2 orally in treatment sequence BCA (Treatment B: new \[2nd generation\] tablets on Day 1 of Week 1; Treatment C: suspension dose of current \[1st generation\] tablets on Day 1 of Week 2; Treatment A: current \[1st generation\] tablets on Day 1 of Week 3 in Cycle 1 (Weeks 1 to 3). All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.
Drug: KCP-330
Also known as: Selinexor
Area Under the Concentration-time Curve From the Time Zero to the Last Non-zero Concentration (AUC0-t) of Selinexor
AUC0-t was defined as area under the concentration-time curve from time zero to the last non-zero concentration.
Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10,18, 24, and 48 hours post-dose
Area Under the Concentration Time Curve From the Time Zero to Extrapolated to Infinity (AUC0-inf) of Selinexor
AUC0-inf was defined as area under the concentration-time curve from time zero to infinity (extrapolated), AUC0-inf was calculated as AUC0-t + Ct/ elimination rate constant (kel), where: Ct = the last observed non- zero concentration.
Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Selinexor
Cmax was defined as maximum observed concentration, taken directly from the plasma concentration data.
Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose
Time of First Maximum Observed Concentration (Tmax) of Selinexor
Tmax was defined as time of first observation of Cmax, taken directly from the plasma concentration data.
Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose
Terminal Phase Half-Life (t1/2) of Selinexor
t1/2 was the terminal phase half-life, it was calculated as ln(2)/kel.
Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose
Apparent Total Body Clearance (CL/F) of Selinexor
Apparent total body clearance was calculated as Dose/AUC0-inf, uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram \[kg\]).
Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose
Apparent Volume of Distribution (Vd/F) of Selinexor
Vd/F was calculated as Dose/ (kel \*AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight (kg).
Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose
Percentage of Participants With Best Overall Response According to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 Criteria
Best overall response rate was defined as the percentage of participants who achieved complete response (CR), and partial response (PR), as assessed by the RECIST v1.1 criteria. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non target) must have reduction in the short axis to less than (\<) 10 millimeter (mm). PR was defined as At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum longest diameter (LD).
Time frame: From the date of first documented response until the date of documented progression or last disease assessment (up to 39 months)
Duration of Stable Disease as Per RECIST v1.1 Criteria
Duration of at least stable disease was defined as the time from the date of first dose of study treatment to first documented radiologic evidence of disease recurrence or progression as per RECIST v1.1 Criteria. Participants without evidence of progression were censored at time of last disease assessment. Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded since the treatment started. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Appearance of one or more new lesions also constituted progressive disease.
Time frame: From the date of first dose of study treatment to first documented radiologic evidence of disease recurrence or progression, censored date (up to 39 months)
Progression Free Survival (PFS) as Per RECIST v1.1 Criteria
PFS was defined as the time from the date of randomization until the first date of Independent Review Committee (IRC)-confirmed PD per RECIST v1.1, or death due to any cause. PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions. Participants who were last known to be alive and without evidence of progression were censored at time of last disease assessment. If date of progression or death occurred after more than 1 missed disease assessment interval, or 30 days after end of treatment, participants were censored at the time of last evaluable disease assessment prior to the missed assessment.
Time frame: From first dose of study treatment to time of disease progression or death, censored date (up to 39 months)
Overall Survival (OS)
OS was defined as the time from date first dose of study treatment to the date of death. Participants who were still alive prior to the data cutoff for final efficacy analysis, or who dropped out prior to study end, were censored at the day they were last known to be alive.
Time frame: From first dose of study treatment to death, censored date (up to 39 months)
Time to Progression (TTP)
TTP was defined as the time from date of first dose of study treatment to first documented evidence of disease recurrence or progression, or death due to disease progression, whichever occurred first. Participants without evidence of progression were censored at time of last evaluable disease assessment.
Time frame: From first dose of study treatment to first documented evidence of disease recurrence or progression, or death, censored date (up to 39 months)
Number of Participants With Growth Modulation Index (GMI) Less Than or Equal to (<=) 1.33 and Greater Than (>) 1.33
GMI was defined as the ratio between the TTP with selinexor and the TTP with the most recent prior treatment. GMI was calculated, using a previously described threshold of 1.3 or greater as a sign of potential drug activity and improved overall survival.
Time frame: Up to 39 months
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a study and which does not necessarily have to have a causal relationship with this treatment. SAE defined as any AE, occurring at any dose (including after the informed consent form was signed and prior to dosing) that and regardless of causality that: results in death, is life-threatening (participant was at immediate risk of death from event as it occurred), requires in-patient hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study treatment through 30 days following last dose or any event considered drug-related by the investigator through the end of the study.
Time frame: From screening up to 30 days post last study drug dose (up to 39 months)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity
AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign, symptom, or medical condition that occur after participant's signed informed consent obtained. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study treatment through 28 days following last dose or any event considered drug-related by the investigator through the end of the study. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening, and Grade 5: death.
Time frame: From screening up to 30 days post last study drug dose (up to 39 months)
Number of Participants With Clinically Significant Laboratory Abnormalities
Number of participants with clinically significant laboratory abnormalities including clinical chemistry, hematology, coagulation and urinalysis. Number of participants with clinically significant laboratory abnormalities which were deemed clinically significant by the investigator were reported.
Time frame: From screening up to 30 days post last study drug dose (up to 39 months)
Number of Participants With Clinically Significant Changes in Vital Signs
Vital signs included blood pressure (systolic blood pressure and diastolic blood pressure). Measurements were made after the participant had been resting supine for a minimum of 5 minutes. Clinically significant findings were defined as such in the opinion of the investigator occurring at any time on treatment from normal pre-dose based on the condition met (Yes/No). Number of participants with clinically significant changes in vital signs with condition (Yes) were only reported.
Time frame: From screening up to 30 days post last study drug dose (up to 39 months)
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECGs)
Twelve lead ECGs were obtained after the participant has rested in a supine position for at least 5 minutes. Clinically significant findings were defined as such in the opinion of the investigator or designated physician occurring at any time on treatment from normal pre-dose.
Time frame: From screening up to 30 days post last study drug dose
This study was conducted at 2 sites in United States and Canada from 30 July 2013 to 21 October 2016.
| Milestone | Arm 1: | Arm 2: | Arm 3: | Arm 4: | Arm 5: | Arm 6: |
|---|---|---|---|---|---|---|
| Started | 10 | 9 | 17 | 7 | 5 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 10 | 9 | 17 | 7 | 5 | 6 |
| Withdrew: Adverse event | 1 | 0 | 2 | 1 | 1 | 0 |
| Withdrew: Physician decision | 1 | 3 | 2 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 3 | 1 | 0 | 0 |
| Withdrew: Disease progression | 7 | 5 | 8 | 4 | 4 | 4 |
| Withdrew: Need of treatment not allowed per protocol | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Intercurrent illness | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 1 | 0 | 1 |
AUC0-t was defined as area under the concentration-time curve from time zero to the last non-zero concentration.
| Nanograms*hour per milliliter (ng*h/mL) | Arms 1 and 2: Treatment A: Fasted, Tablet Formulation | Arms 1 and 2: Treatment B: High-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment C: Low-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment D: Low-Fat Meal, Capsule Formulation | Arms 4, 5, and 6: Treatment A: First Generation Tablet | Arms 4, 5, and 6: Treatment B: Second Generation Tablet | Arms 4, 5, and 6: Treatment C: Oral Suspension |
|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve From the Time Zero to the Last Non-zero Concentration (AUC0-t) of Selinexor | 2752 ± 37.5 | 3175 ± 25.3 | 3280 ± 19.3 | 3342 ± 21.4 | 4086 ± 22.3 | 4220 ± 22.0 | 3955 ± 21.2 |
AUC0-inf was defined as area under the concentration-time curve from time zero to infinity (extrapolated), AUC0-inf was calculated as AUC0-t + Ct/ elimination rate constant (kel), where: Ct = the last observed non- zero concentration.
| ng*h/mL | Arms 1 and 2: Treatment A: Fasted, Tablet Formulation | Arms 1 and 2: Treatment B: High-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment C: Low-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment D: Low-Fat Meal, Capsule Formulation | Arms 4, 5, and 6: Treatment A: First Generation Tablet | Arms 4, 5, and 6: Treatment B: Second Generation Tablet | Arms 4, 5, and 6: Treatment C: Oral Suspension |
|---|---|---|---|---|---|---|---|
| Area Under the Concentration Time Curve From the Time Zero to Extrapolated to Infinity (AUC0-inf) of Selinexor | 2969 ± 34.1 | 3412 ± 23.8 | 3483 ± 18.1 | 3561 ± 20.6 | 4117 ± 22.4 | 4250 ± 21.8 | 4002 ± 21.1 |
Cmax was defined as maximum observed concentration, taken directly from the plasma concentration data.
| Nanogram per milliliter (ng/mL) | Arms 1 and 2: Treatment A: Fasted, Tablet Formulation | Arms 1 and 2: Treatment B: High-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment C: Low-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment D: Low-Fat Meal, Capsule Formulation | Arms 4, 5, and 6: Treatment A: First Generation Tablet | Arms 4, 5, and 6: Treatment B: Second Generation Tablet | Arms 4, 5, and 6: Treatment C: Oral Suspension |
|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Selinexor | 355 ± 52.6 | 404 ± 39.1 | 436 ± 21.9 | 429 ± 29.1 | 519 ± 34.4 | 527 ± 30.7 | 450 ± 52.8 |
Tmax was defined as time of first observation of Cmax, taken directly from the plasma concentration data.
| Hour | Arms 1 and 2: Treatment A: Fasted, Tablet Formulation | Arms 1 and 2: Treatment B: High-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment C: Low-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment D: Low-Fat Meal, Capsule Formulation | Arms 4, 5, and 6: Treatment A: First Generation Tablet | Arms 4, 5, and 6: Treatment B: Second Generation Tablet | Arms 4, 5, and 6: Treatment C: Oral Suspension |
|---|---|---|---|---|---|---|---|
| Time of First Maximum Observed Concentration (Tmax) of Selinexor | 1.5 (1.0 to 6.1) | 3.4 (1.5 to 8.0) | 3.4 (1.4 to 6.1) | 3.8 (1.5 to 5.0) | 2.1 (0.6 to 5.1) | 3.0 (1.0 to 4.2) | 1.6 (1.0 to 9.7) |
t1/2 was the terminal phase half-life, it was calculated as ln(2)/kel.
| Hour | Arms 1 and 2: Treatment A: Fasted, Tablet Formulation | Arms 1 and 2: Treatment B: High-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment C: Low-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment D: Low-Fat Meal, Capsule Formulation | Arms 4, 5, and 6: Treatment A: First Generation Tablet | Arms 4, 5, and 6: Treatment B: Second Generation Tablet | Arms 4, 5, and 6: Treatment C: Oral Suspension |
|---|---|---|---|---|---|---|---|
| Terminal Phase Half-Life (t1/2) of Selinexor | 6.2 ± 1.71 | 5.9 ± 1.36 | 5.6 ± 1.00 | 5.7 ± 1.06 | 6.7 ± 1.34 | 6.6 ± 1.14 | 6.5 ± 1.51 |
Apparent total body clearance was calculated as Dose/AUC0-inf, uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram \[kg\]).
| Liter per hour per kilogram (L/h/kg) | Arms 1 and 2: Treatment A: Fasted, Tablet Formulation | Arms 1 and 2: Treatment B: High-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment C: Low-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment D: Low-Fat Meal, Capsule Formulation | Arms 4, 5, and 6: Treatment A: First Generation Tablet | Arms 4, 5, and 6: Treatment B: Second Generation Tablet | Arms 4, 5, and 6: Treatment C: Oral Suspension |
|---|---|---|---|---|---|---|---|
| Apparent Total Body Clearance (CL/F) of Selinexor | 0.3 ± 32.1 | 0.22 ± 21.3 | 0.22 ± 16.3 | 0.21 ± 18.7 | 0.21 ± 20.6 | 0.20 ± 16.6 | 0.21 ± 14.2 |
Vd/F was calculated as Dose/ (kel \*AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight (kg).
| Liter per kilogram (L/kg) | Arms 1 and 2: Treatment A: Fasted, Tablet Formulation | Arms 1 and 2: Treatment B: High-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment C: Low-Fat Meal, Tablet Formulation | Arms 1 and 2: Treatment D: Low-Fat Meal, Capsule Formulation | Arms 4, 5, and 6: Treatment A: First Generation Tablet | Arms 4, 5, and 6: Treatment B: Second Generation Tablet | Arms 4, 5, and 6: Treatment C: Oral Suspension |
|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vd/F) of Selinexor | 2.2 ± 49.5 | 1.8 ± 32.3 | 1.7 ± 26.1 | 1.7 ± 26.6 | 2.0 ± 16.9 | 1.9 ± 18.3 | 1.9 ± 18.2 |
Best overall response rate was defined as the percentage of participants who achieved complete response (CR), and partial response (PR), as assessed by the RECIST v1.1 criteria. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non target) must have reduction in the short axis to less than (\<) 10 millimeter (mm). PR was defined as At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum longest diameter (LD).
| Percentage of participants | Liposarcoma | Leiomyosarcoma | Other Sarcoma |
|---|---|---|---|
| Complete Response (CR) | 0 | 0 | 0 |
| Partial Response (PR) | 0 | 0 | 0 |
Duration of at least stable disease was defined as the time from the date of first dose of study treatment to first documented radiologic evidence of disease recurrence or progression as per RECIST v1.1 Criteria. Participants without evidence of progression were censored at time of last disease assessment. Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded since the treatment started. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Appearance of one or more new lesions also constituted progressive disease.
| Months | Liposarcoma | Leiomyosarcoma | Other Sarcoma |
|---|---|---|---|
| Duration of Stable Disease as Per RECIST v1.1 Criteria | 7.49 (3.55 to NA) | 3.94 (1.64 to 5.55) | 8.34 (3.09 to NA) |
PFS was defined as the time from the date of randomization until the first date of Independent Review Committee (IRC)-confirmed PD per RECIST v1.1, or death due to any cause. PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions. Participants who were last known to be alive and without evidence of progression were censored at time of last disease assessment. If date of progression or death occurred after more than 1 missed disease assessment interval, or 30 days after end of treatment, participants were censored at the time of last evaluable disease assessment prior to the missed assessment.
| Months | Liposarcoma | Leiomyosarcoma | Other Sarcoma |
|---|---|---|---|
| Progression Free Survival (PFS) as Per RECIST v1.1 Criteria | 4.44 (2.07 to 7.49) | 3.52 (1.48 to 5.55) | 1.84 (1.02 to 3.58) |
OS was defined as the time from date first dose of study treatment to the date of death. Participants who were still alive prior to the data cutoff for final efficacy analysis, or who dropped out prior to study end, were censored at the day they were last known to be alive.
| Months | Liposarcoma | Leiomyosarcoma | Other Sarcoma |
|---|---|---|---|
| Overall Survival (OS) | 9.00 (4.76 to NA) | 7.03 (5.75 to NA) | NA (3.38 to NA) |
TTP was defined as the time from date of first dose of study treatment to first documented evidence of disease recurrence or progression, or death due to disease progression, whichever occurred first. Participants without evidence of progression were censored at time of last evaluable disease assessment.
| Months | Liposarcoma | Leiomyosarcoma | Other Sarcoma |
|---|---|---|---|
| Time to Progression (TTP) | 4.44 (2.07 to NA) | 3.52 (1.48 to 5.55) | 1.74 (1.02 to 5.55) |
GMI was defined as the ratio between the TTP with selinexor and the TTP with the most recent prior treatment. GMI was calculated, using a previously described threshold of 1.3 or greater as a sign of potential drug activity and improved overall survival.
| Participants | Liposarcoma | Leiomyosarcoma | Other Sarcoma |
|---|---|---|---|
| GMI <= 1.33 | 11 | 8 | 17 |
| GMI > 1.33 | 7 | 4 | 3 |
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a study and which does not necessarily have to have a causal relationship with this treatment. SAE defined as any AE, occurring at any dose (including after the informed consent form was signed and prior to dosing) that and regardless of causality that: results in death, is life-threatening (participant was at immediate risk of death from event as it occurred), requires in-patient hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study treatment through 30 days following last dose or any event considered drug-related by the investigator through the end of the study.
| Participants | Arm 1: | Arm 2: | Arm 3: | Arm 4: | Arm 5: | Arm 6: |
|---|---|---|---|---|---|---|
| Participants with TEAEs | 10 | 9 | 17 | 7 | 5 | 6 |
| Participants with Serious TEAEs | 4 | 5 | 5 | 2 | 2 | 4 |
AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign, symptom, or medical condition that occur after participant's signed informed consent obtained. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study treatment through 28 days following last dose or any event considered drug-related by the investigator through the end of the study. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening, and Grade 5: death.
| Participants | Arm 1: | Arm 2: | Arm 3: | Arm 4: | Arm 5: | Arm 6: |
|---|---|---|---|---|---|---|
| Grade 1: Mild | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 2: Moderate | 3 | 2 | 2 | 1 | 1 | 1 |
| Grade 3: Severe | 5 | 5 | 14 | 3 | 2 | 4 |
| Grade 4: Life Threatening | 2 | 1 | 0 | 3 | 1 | 1 |
| Grade 5: Fatal | 0 | 1 | 1 | 0 | 1 | 0 |
Number of participants with clinically significant laboratory abnormalities including clinical chemistry, hematology, coagulation and urinalysis. Number of participants with clinically significant laboratory abnormalities which were deemed clinically significant by the investigator were reported.
| Participants | Arm 1: | Arm 2: | Arm 3: | Arm 4: | Arm 5: | Arm 6: |
|---|---|---|---|---|---|---|
| Hematology | 1 | 2 | 7 | 1 | 2 | 1 |
| Clinical Chemistry | 4 | 1 | 7 | 1 | 1 | 1 |
| Coagulation: Prothrombin intl. normalized ratio | 0 | 0 | 1 | 0 | 0 | 0 |
| Urinalysis | 0 | 0 | 0 | 0 | 0 | 0 |
Vital signs included blood pressure (systolic blood pressure and diastolic blood pressure). Measurements were made after the participant had been resting supine for a minimum of 5 minutes. Clinically significant findings were defined as such in the opinion of the investigator occurring at any time on treatment from normal pre-dose based on the condition met (Yes/No). Number of participants with clinically significant changes in vital signs with condition (Yes) were only reported.
| Participants | Arm 1: | Arm 2: | Arm 3: | Arm 4: | Arm 5: | Arm 6: |
|---|---|---|---|---|---|---|
| Systolic Blood Pressure: < 100 mmHg (Yes) | 2 | 5 | 8 | 4 | 3 | 3 |
| Systolic Blood Pressure: > 10 mmHg decrease from baseline (Yes) | 3 | 7 | 14 | 6 | 5 | 5 |
| Systolic Blood Pressure: > 20 mmHg decrease from baseline (Yes) | 2 | 4 | 10 | 4 | 1 | 3 |
| Systolic Blood Pressure: < 100 mmHg and > 10 mmHg decrease from baseline (Yes) | 1 | 4 | 7 | 3 | 3 | 2 |
| Systolic Blood Pressure: < 100 mmHg and > 20 mmHg decrease from baseline (Yes) | 1 | 1 | 4 | 2 | 1 | 2 |
| Diastolic Blood Pressure: < 60 mmHg (Yes) | 2 | 3 | 10 | 2 | 2 | 2 |
| Diastolic Blood Pressure: > 5 mmHg decrease from baseline (Yes) | 8 | 7 | 15 | 6 | 4 | 5 |
| Diastolic Blood Pressure: > 10 mmHg decrease from baseline (Yes) | 5 | 5 | 12 | 5 | 3 | 4 |
| Diastolic Blood Pressure: < 60 mmHg and > 5 mmHg decrease from baseline (Yes) | 2 | 2 | 9 | 2 | 1 | 2 |
| Diastolic Blood Pressure: < 60 mmHg and > 10 mmHg decrease from baseline (Yes) | 2 | 2 | 9 | 2 | 0 | 2 |
| Systolic Blood Pressure : > 140 mmHg (Yes) | 2 | 3 | 6 | 2 | 3 | 3 |
| Systolic Blood Pressure: > 160 mmHg (Yes) | 0 | 0 | 1 | 1 | 0 | 0 |
| Systolic Blood Pressure: > 10 mmHg increase from baseline (Yes) | 2 | 6 | 11 | 3 | 4 | 5 |
| Systolic Blood Pressure: > 20 mmHg increase from baseline (Yes) | 1 | 5 | 3 | 1 | 1 | 4 |
| Systolic Blood Pressure: > 160 mmHg and > 10 mmHg increase from baseline (Yes) | 0 | 0 | 1 | 1 | 0 | 0 |
| Systolic Blood Pressure: > 160 mmHg and > 20 mmHg increase from baseline (Yes) | 0 | 0 | 0 | 0 | 0 | 0 |
| Diastolic Blood Pressure: > 90 mmHg (Yes) | 4 | 3 | 6 | 2 | 3 | 3 |
| Diastolic Blood Pressure: > 100 mmHg (Yes) | 0 | 0 | 1 | 1 | 0 | 0 |
| Diastolic Blood Pressure: > 5 mmHg increase from baseline (Yes) | 6 | 5 | 13 | 4 | 4 | 6 |
| Diastolic Blood Pressure: > 10 mmHg increase from baseline (Yes) | 2 | 4 | 8 | 2 | 3 | 4 |
| Diastolic Blood Pressure: > 100 mmHg and > 5 mmHg increase from baseline (Yes) | 0 | 0 | 1 | 1 | 0 | 0 |
| Diastolic Blood Pressure: > 100 mmHg and > 10 mmHg increase from baseline (Yes) | 0 | 0 | 0 | 1 | 0 | 0 |
Twelve lead ECGs were obtained after the participant has rested in a supine position for at least 5 minutes. Clinically significant findings were defined as such in the opinion of the investigator or designated physician occurring at any time on treatment from normal pre-dose.
| Participants | Arm 1: | Arm 2: | Arm 3: | Arm 4: | Arm 5: | Arm 6: |
|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Electrocardiogram (ECGs) | 2 | 0 | 1 | 0 | 0 | 0 |
Collected over From screening up to 30 days post last study drug dose (up to 39 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: | 2/10 (20%) | 4/10 (40%) | 10/10 (100%) |
| Arm 2: | 2/9 (22.2%) | 5/9 (55.6%) | 9/9 (100%) |
| Arm 3: | 1/17 (5.9%) | 5/17 (29.4%) | 17/17 (100%) |
| Arm 4: | 3/7 (42.9%) | 2/7 (28.6%) | 7/7 (100%) |
| Arm 5: | 3/5 (60%) | 2/5 (40%) | 5/5 (100%) |
| Arm 6: | 2/6 (33.3%) | 4/6 (66.7%) | 6/6 (100%) |
| Event | Arm 1: | Arm 2: | Arm 3: | Arm 4: | Arm 5: | Arm 6: |
|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/10 | 1/9 | 0/17 | 0/7 | 1/5 | 0/6 |
| DeathGeneral disorders | 0/10 | 1/9 | 0/17 | 0/7 | 1/5 | 0/6 |
| SepsisInfections and infestations | 2/10 | 0/9 | 0/17 | 0/7 | 0/5 | 0/6 |
| Lung infectionInfections and infestations | 0/10 | 0/9 | 0/17 | 0/7 | 1/5 | 0/6 |
| FallInjury, poisoning and procedural complications | 0/10 | 0/9 | 0/17 | 0/7 | 1/5 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 0/10 | 0/9 | 0/17 | 0/7 | 0/5 | 1/6 |
| CataractEye disorders | 0/10 | 0/9 | 0/17 | 0/7 | 0/5 | 1/6 |
| Small intestinal obstructionGastrointestinal disorders | 1/10 | 1/9 | 0/17 | 0/7 | 0/5 | 1/6 |
| Wound complicationInjury, poisoning and procedural complications | 0/10 | 0/9 | 0/17 | 0/7 | 0/5 | 1/6 |
| EmbolismVascular disorders | 1/10 | 0/9 | 0/17 | 0/7 | 0/5 | 1/6 |
| Event | Arm 1: | Arm 2: | Arm 3: | Arm 4: | Arm 5: | Arm 6: |
|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 2/10 | 8/9 | 9/17 | 1/7 | 5/5 | 3/6 |
| NauseaGastrointestinal disorders | 7/10 | 8/9 | 17/17 | 6/7 | 4/5 | 5/6 |
| FatigueGeneral disorders | 8/10 | 9/9 | 16/17 | 4/7 | 5/5 | 6/6 |
| AnaemiaBlood and lymphatic system disorders | 3/10 | 7/9 | 12/17 | 1/7 | 4/5 | 5/6 |
| ConstipationGastrointestinal disorders | 5/10 | 5/9 | 12/17 | 3/7 | 2/5 | 5/6 |
| LeukopeniaBlood and lymphatic system disorders | 2/10 | 7/9 | 6/17 | 0/7 | 2/5 | 3/6 |
| VomitingGastrointestinal disorders | 5/10 | 5/9 | 12/17 | 4/7 | 3/5 | 3/6 |
| DysgeusiaNervous system disorders | 3/10 | 5/9 | 8/17 | 0/7 | 1/5 | 4/6 |
| DizzinessNervous system disorders | 2/10 | 3/9 | 11/17 | 1/7 | 2/5 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 6/10 | 4/9 | 5/17 | 1/7 | 1/5 | 3/6 |
Safety population consisted of all participants who received at least one dose of selinexor.
| Age, Continuous(Years) | Arm 1: | Arm 2: | Arm 3: | Arm 4: | Arm 5: | Arm 6: | Total |
|---|---|---|---|---|---|---|---|
| Mean | 51.7 ± 12.72 | 57.6 ± 17.18 | 59.9 ± 13.90 | 53.4 ± 8.10 | 43.6 ± 19.32 | 53.8 ± 11.62 | 55.0 ± 14.22 |
| Sex: Female, Male(Participants) | Arm 1: | Arm 2: | Arm 3: | Arm 4: | Arm 5: | Arm 6: | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 7 | 11 | 3 | 3 | 3 | 31 |
| Male | 6 | 2 | 6 | 4 | 2 | 3 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1: | Arm 2: | Arm 3: | Arm 4: | Arm 5: | Arm 6: | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 9 | 7 | 16 | 7 | 4 | 6 | 49 |
| Unknown or Not Reported | 1 | 2 | 1 | 0 | 1 | 0 | 5 |
| Race/Ethnicity, Customized(Participants) | Arm 1: | Arm 2: | Arm 3: | Arm 4: | Arm 5: | Arm 6: | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 2 | 2 | 1 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 | 1 | 0 | 3 |
| White | 8 | 9 | 12 | 4 | 3 | 5 | 41 |
| Unknown or Not Reported | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| Other | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
Plan to share: Undecided
Ran from Jul 2013 to primary completion in Oct 2016, 38 months.
Results were first posted in Jan 2024, 7 years 2 months after primary completion.
Of 72 industry-sponsored phase 1 interventional studies under Sarcoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 66. This study's 38 months is below that.
Counting every sponsor, half of 161 studies reached it within 56 months; a quarter within 35 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selinexor